AUAUniversity

Emerging Treatment of M0 CRPC: Update on the AUA/SUO Guidelines is the second podcast in a 4-part series. Topics will include “M0 CRPC: Emerging Treatment Options” and “MDC and Review of CRPC Guidelines”.

CME Available: auau.auanet.org/node/19907

AUA2018 Take Home Messages Basic Sciences - Trauma by American Urological Association

The Changing Landscape of Advanced Prostate Cancer Management: What You Need to Know is the first podcast in a 4-part series. Topics will include "Initial Management and Imaging of Advanced Prostate Cancer" and "Chemo-hormonal Therapy for Metastatic Hormone-Sensitive Prostate Cancer ".

CME Available: https://auau.auanet.org/node/19906

This course will include short didactic lectures followed by case presentations to give attendees an understanding of the many new FDA-approved agents, as well as existing standard therapies, for advanced prostate cancer-both non-metastatic and metastatic CRPC. Particular attention will be devoted to sequencing the new agents and positioning them as compared to older existing therapies. The cost effectiveness of new and existing agents will also be addressed.

CME Available: https://auau.auanet.org/content/novel-agents-concepts-management-hormone-na%C3%AFve-castrate-resistant-prostate-cancer-webcast

This course will provide a practical, evidence-based approach for the management of everyday problems in the management of prostate cancer, using a case-based approach with examples from real practice. Cases will illustrate contemporary management of early and late stage disease with emphasis on how new molecular diagnostic and prognostic tests (PCA3, MDx Confirm, Mitomics, Prolaris, Oncotype Dx Prostate, Decipher, and others) can be used for improved clinical decision making in screening, decisions on initial biopsy and rebiopsy, choosing and following men for active surveillance, and managing PSA failures. In addition, best practice use of newer agents for management of castrate-resistant disease will be reviewed, including the potential for use of targeted therapies based on genomic analysis of advanced tumors. The course will be of interest to individuals at all levels of clinical experience.

CME Available: https://auau.auanet.org/content/management-prostate-cancer-case-based-approach-emphasis-integrating-new-molecular-7

The goal of the course is to provide both a basic and real-world application of immunotherapy for genitourinary oncology. The course is directed towards the urologist with an interest, but no prior experience delivering immunotherapy agents to patients with bladder and kidney cancer (with possible application to prostate cancer in the future). Starting with innovating breakthroughs, new therapies and their side-effects, the course will also cover common side-effects and biomarkers to risk stratify patients. We will plan to discuss real world-challenges in starting an immunotherapy program, from regulatory requirements to coding and billing for systemic therapies.

CME Available: https://auau.auanet.org/content/immunotherapy-urologist-basic-principles-adverse-effects-drug-delivery-webcast-019ic-2018

This course will offer a review of what faculty believe are the most important articles in the English-speaking literature on prostate cancer from May 2017 to April 2018. Focus will be placed on articles that have relevance to clinical practice, including both research and clinical articles.

CME Available: https://auau.auanet.org/content/prostate-cancer-update-webcast-063ic-2018

Review of current chemotherapy and immunotherapy regimens for genitourinary malignancies, including bladder, renal, and prostate cancers. Indications, outcomes, and toxicities will be discussed as well as clinical trial concepts. Survivorship issues will also be a focus of the session, which will include short, direct didactic lectures as well as a panel discussion with an interactive component. Standard of care chemotherapy regimens (eg MVAC for urothelial carcinoma) as well as newer immunotherapy options (eg checkpoint inhibition for renal cell carcinoma) will be included. Session objectives will include familiarity with systemic therapy regimens for these malignancies as well as their specific expected outcomes and side effects.

CME Available: https://auau.auanet.org/content/chemotherapy-immunotherapy-options-genitourinary-malignancies-primer-advanced-practice

We will discuss common PSA dilemmas: 1. Who should be screened? 2. What is the role of MRI in biopsy naive and men with prior negative biopsy? 3. What other markers can be used to determine whether biopsy or rebiopsy is warranted? 4. Whats the optimal biopsy strategy: Transrectal, transperineal, MRI-cognitive, MRI fusion? 5. Discuss Active Surveillance, Rad Px, XRT and focal therapy pros and cons for PSA-detected cancer. 6. What is role of adjuvant v. salvage XRT post-RP? 7. Review new PET scans for biochemically recurrent disease after RP or XRT. 8. Discuss roles of ADT, chemotherapy, and other agents (PARP inhibitors, vaccines, immunooncologic agents) in men with advanced and metastatic disease.

CME Available: https://auau.auanet.org/content/management-common-dilemmas-prostate-cancer-diagnosis-staging-treatment-webcast-058ic-2018

The "Live from AUA2018" Highlights in Renal Cell Carcinoma series is comprised of three panel discussions which will focus on:

Discussing the evolving landscape of adjuvant therapy for the treatment of kidney cancer and debating the elements of disagreement in this area.

Differentiating the roles of urologist and medical oncologist in the care of patients with kidney cancer.

Appreciating the patient’s journey through RCC and identifying their needs as it relates to the coordination of care between the urologists and medical oncologist.

CME: https://auau.auanet.org/content/highlights-renal-cell-carcinoma-coordination-care-patients-journey-2018